Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Acasti Pharma Inc ACST

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.


NDAQ:ACST - Post by User

Post by LittleHedgeon Jan 08, 2020 9:54am
242 Views
Post# 30530027

I dont think it is being manipulated

I dont think it is being manipulatedACST is small market cap and bit ‘potential’ I think are the 2 reasons this stock is going up and down while smaller investors grapple with balancing their fear with their greed.

If it were being manipulated, it would be pretty obvious soon if once records are updated that large holders have shifted their positions one way or another and if they had (e.g. between mid Dec and Jan) in a way that reflected the results of P3 this stock would be ruined and people would be investigated for insider trading.

I am of the camp that this is currently a volatile small cap which is being heavily day traded, too many stop losses being set and an occasional fool selling at market, I am not sure there are enough available shares to keep this stable in the short term.

I think the Company has great promise, I have a modest holding that I am going to hang on to.


<< Previous
Bullboard Posts
Next >>